Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms

被引:11
作者
Bayat, Maryam [1 ]
Asemani, Yahya [2 ]
Najafi, Sajad [3 ]
机构
[1] Shiraz Univ Med Sci, Dept Immunol, Shiraz, Iran
[2] Shahid Beheshti Univ Med Sci, Dept Immunol, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Student Res Comm, Tehran, Iran
关键词
COVID-19; Vaccine; Design; SARS-CoV2; Adjuvant; RESPIRATORY SYNDROME CORONAVIRUS; PROTECTIVE IMMUNITY; VIRUS; IMMUNIZATION; PROTEIN; EPITOPE; MICE; SARS; RESPONSES; LESSONS;
D O I
10.1016/j.intimp.2021.107679
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The calamity of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), COVID-19, is still a global human tragedy. To date, no specific antiviral drug or therapy has been able to break the widespread of SARS-CoV2. It has been generally believed that stimulating protective immunity via universal vaccination is the individual strategy to manage this pandemic. Achieving an effective COVID-19 vaccine requires attention to the immunological and non-immunological standpoints mentioned in this article. Here, we try to introduce the considerable immunological aspects, potential antigen targets, appropriate adjuvants as well as key points in the various stages of COVID-19 vaccine development. Also, the principal features of the preclinical and clinical studies of pioneering COVID-19 vaccine candidates were pointed out by reviewing the available information. Finally, we discuss the key challenges in the successful design of the COVID-19 vaccine and address the most fundamental strengths and weaknesses of common vaccine platforms.
引用
收藏
页数:15
相关论文
共 137 条
[1]   Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of the COVID-19 and biomedical interventions [J].
Abdullahi, Idris N. ;
Emeribe, Anthony U. ;
Ajayi, Onaoluwa A. ;
Oderinde, Bamidele S. ;
Amadu, Dele O. ;
Osuji, Ahaneku I. .
JOURNAL OF TAIBAH UNIVERSITY MEDICAL SCIENCES, 2020, 15 (04) :258-264
[2]   Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens [J].
Afkhami, Sam ;
Yao, Yushi ;
Xing, Zhou .
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2016, 3 :16030
[3]   Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies [J].
Ahmed, Syed Faraz ;
Quadeer, Ahmed A. ;
McKay, Matthew R. .
VIRUSES-BASEL, 2020, 12 (03)
[4]   Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate [J].
Almazan, Fernando ;
DeDiego, Marta L. ;
Sola, Isabel ;
Zuniga, Sonia ;
Nieto-Torres, Jose L. ;
Marquez-Jurado, Silvia ;
Andres, German ;
Enjuanes, Luis .
MBIO, 2013, 4 (05)
[5]  
Andrew S, 2020, IMPERIAL SOCIAL ENTE
[6]  
[Anonymous], 2020, COVAXIN BBV152 SHOWS
[7]   A brief review of socio-economic and environmental impact of Covid-19 [J].
Bashir, Muhammad Farhan ;
Ma, Benjiang ;
Shahzad, Luqman .
AIR QUALITY ATMOSPHERE AND HEALTH, 2020, 13 (12) :1403-1409
[8]   An overview of some potential immunotherapeutic options against COVID-19 [J].
Bayat, Maryam ;
Asemani, Yahya ;
Mohammadi, Mohammad Reza ;
Sanaei, Mahsa ;
Namvarpour, Mozhdeh ;
Eftekhari, Reyhaneh .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 95
[9]   What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens? [J].
Belyakov, Igor M. ;
Ahlers, Jeffrey D. .
JOURNAL OF IMMUNOLOGY, 2009, 183 (11) :6883-6892
[10]   Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach [J].
Bhattacharya, Manojit ;
Sharma, Ashish R. ;
Patra, Prasanta ;
Ghosh, Pratik ;
Sharma, Garima ;
Patra, Bidhan C. ;
Lee, Sang-Soo ;
Chakraborty, Chiranjib .
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (06) :618-631